Exeltis

Q: What is Exeltis’s industry?

Exeltis is in the industry of: Manufacturing , Pharmaceuticals , Drug Stores & Pharmacies

Q: Who are Exeltis’s main competitors?

Exeltis's main competitors are: Sprim , Servier , Ipsen Pharma , EMD Serono

Manufacturing · New Jersey, United States · 4,000 Employees

Get Full Access

Who is Exeltis

Exeltis is a fast-growing division of Madrid-based Insud Pharma, an integrated health sciences group. It has developed a leading position in the women's healthsector, where it continues to discover, develop, produce and seek new medicines and medical devices to improve the health and wellbeing of women around the world. Exeltis strives to provide care for women throughout their lives. Exeltis offers a broad portfolio of products to respond to patients' needs in Women's Health including contraception, pregnancy, birth, and menopause and has expanded its research in recent years to Central Nervous System (CNS), ophthalmology and endocrinology.Read More

Headquarters:

180 Park Ave, Ste 101, Florham Park, New Jersey, 07932, United States

Phone Number:

(973) 324-0200

Website:

www.exeltis.com

Revenue:

$763 Million

Is this data correct?

View contact profiles from Exeltis

SIC Code 28,283

NAICS Code 44,4461

Top Competitors of Exeltis

Sprim

600

$62 Million

Servier

22,500

$5 Billion

Ipsen Pharma

5,700

$2 Billion

EMD Serono

4,000

$758 Million

Amarin Corporation

1,000

$614 Million

Takeda Pharmaceuticals U.S.A.

18,000

$6 Billion

Exeltis's Org Chart

Lucas Sigman

Chief Executive Officer

Phone

Claudia Nohara

Chief Financial Officer

Phone

Salustiano Perez

President

Phone

Exeltis Company Metrics

Company Insights

Employee Growth Rate

Revenue

Quarter	Revenue
'21 - Q1	763380000
'21 - Q2	763380000

Acquisitions & Subsidiaries

Quinnova Pharmaceuticals

See More Acquisitions & Subsidiaries

Exeltis's Tech Stack

Microsoft Excel

Microsoft

Ativo

Ativo.com

Teamwork

Teamwork.com

Tableau

See more technologies

Exeltis News & Media

Luye Pharma Grants Exeltis Exclusive Commercialization Rights to Its Innovative Alzheimer's Disease Treatment Rivastigmine Multi-Day Transdermal Patch in Mexico and Poland

BASEL, Switzerland, March 31, 2022 /PRNewswire/ -- Luye Pharma Group (Luye Pharma) today announced that its subsidiary Luye Pharma Switzerland AG has entered into agreements with Exeltis Pharma México, S.A. de C.V and Exeltis Pharmaceuticals Holding, S.L (Exeltis), under which the company...

Lupin Signs Promotional Agreement with Exeltis on SOLOSEC® (secnidazole) expanding access for Adult Women Suffering with Bacterial Vaginosis and Adults with Trichomoniasis

BALTIMORE, Jan. 27, 2022 /PRNewswire/ -- Lupin Pharmaceuticals Inc., (Lupin), and Exeltis USA Inc. announced a promotional agreement for Exeltis to promote SOLOSEC® along with Exeltis' existing line of Women's Health products, further enhancing value to OBGYNs and their patients. SOLOSEC®...

IntelGenx Announces Market Launch of RIZAPORT® in Spain

SAINT LAURENT, Quebec, Sept. 07, 2021 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX V:IGX)(OTCQB:IGXT) (the "Company" or "IntelGenx") today announced that Exeltis Healthcare S.L. (“Exeltis”), its commercialization partner in the European Union (“EU”) for RIZAPORT®, a unique for the treatment of acute migraines, has launched the product in Spain.